‘A dark day for U.K. science’ as Britain votes to break with EU
28 June 2016
There is alarm, concern and even heartbreak across the biotech and pharma industry and among leading scientists at the vote to leave the EU. “This is not the outcome the Bioindustry Association wanted,” Steve Bates, CEO told BioWorld Today. “Key questions about the regulation of medicine, access to the single market and talent, intellectual property and the precise nature of the future relationship of the U.K. with Europe, are now upon us,” Bates said.
27 June 2016
Tobira Therapeutics, Inc. (NASDAQ: TBRA), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel treatments for liver and inflammatory diseases, today announced that data from multiple animal models showed that cenicriviroc (CVC), a potent inhibitor of two chemokine receptors, displayed potent anti-inflammatory and anti-fibrotic activity in multiple organs including liver and kidney.
Uncertainty for biotech as U.K. exits EU, prime minister to resign
27 June 2016
It was a shock result for the U.K. this morning as the public decided by a narrow margin of 52-48 to leave the European Union, in what will have a profound impact on the economy and the life sciences industry--and has already claimed the scalp of the country's leader.
Cancer immunotherapy may increase risk of developing rheumatologic disorders: Johns Hopkins study
27 June 2016
Johns Hopkins University researchers have found a link between cancer immunotherapy drugs and an increased risk of developing rheumatologic disorders—that they expect to only be exacerbated as their use increases. They conducted what’s thought to be the largest published study of patients taking immunotherapies aimed at examining the potential connection between the drug class and these sorts of diseases.
Manufactured stem cells to advance clinical research
27 June 2016
Researchers supported by the National Institutes of Health developed a clinical-grade stem cell line, which has the potential to accelerate the advance of new medical applications and cell-based therapies for millions of people suffering from such ailments as Alzheimer’s disease, Parkinson’s disease, spinal cord injury, diabetes, and muscular dystrophy. The stem cells were developed by isolating human umbilical cord blood cells following a healthy birth, and coaxing them back into a pluripotent state, or one in which they have the potential to develop into any cell type in the body. Cells developed in this manner are called induced pluripotent stem cells (iPSCs). With NIH support, these cells were manufactured by Lonza, Walkersville, Maryland, and described in a publication by Behnam Baghbaderani, Ph.D., and colleagues in Stem Cell Reports.
Scoring the 5 top phase III drugs in the global pipeline
27 June 2016
Their phase III list is dominated by Roche, which is pulling off a string of blockbuster approvals. Regeneron and Sanofi, perhaps the best partners in biotech, have a clear shot with dupilumab. Lilly, which has begun to rack up badly needed successes in Phase III, is expected to score with abemaciclib (though CDK 4/6 will be competitive).
Epic Sciences Introduces Sensitive HRD Liquid Biopsy Test for PARP Inhibitor Clinical Trials
24 June 2016
Epic Sciences unveiled a liquid biopsy test that more sensitively detects cancers susceptible to PARP inhibitors by targeting homologous recombination deficiency (HRD) in individual circulating tumor cells (CTCs). The new test has already been incorporated into numerous clinical studies of HRD-targeted therapeutics in multiple cancer types.
Agencies push bug drug pipeline but development lacks market pull
24 June 2016
Efforts to improve the treatment of multidrug-resistant bacterial infections begin with the pipeline, and pipelines emerge from scientific prowess and dealmaking. Despite public rhetoric about confronting the superbug threat globally, experts contend that the cupboard of innovative treatments to address these pathogens is meager and the supply of scientists needed to restock the shelves is scarce.
Drug resistance specter is fact of life for antibiotics
24 June 2016
In the justified worries about drug resistance, it tends to get somewhat lost that there is, as yet, no completely untreatable superbug. The colistin resistance gene mcr-1 that was detected on plasmids in China and Europe in 2015, and in the US in 2016, has not yet met up with a bacterium that is resistant to all other drugs.
Study: Shorter, higher-dose radiotherapy effective for prostate cancer
24 June 2016
A shorter course of radiotherapy with fewer sessions and higher dosage is as effective as the standard of care in treating prostate cancer, a U.K. study found. Switching over to this shorter schedule would not only benefit patients, but also help the National Health Service save tens of millions of pounds.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Big Pharma’s ROI for drug R&D saw 'welcome' rebound in 2023: report
25 April 2024
Orphan drug market to reach $270B by 2028 : Evaluate
25 April 2024
Russian drug for the treatment of viral hepatitis will be exempt from duty in Mongolia
24 April 2024
PM Mishustin: “We need to increase the production of vital and essential drugs in Russia”
24 April 2024